ReviewComprehensive Physiology2026
GLP-1 at the Metabolic-Cognitive Interface: Reward, Affect, and Memory.
Review in Comprehensive Physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Resolution of anhedonia-like symptoms in patients treated for obesity with tirzepatide: A three-case series.Obesity pillars · 2026Article
- Suicidality as a potential risk and therapeutic target during widespread GLP-1 receptor agonists use: implications of inflammation.Frontiers in synaptic neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Glucagon-like peptide-1 (GLP-1) is a nutrient-responsive hormone classically associated with glucose homeostasis and food intake control, yet its receptor is broadly expressed throughout the central nervous system (CNS) in circuits governing complex cognitive processes. Here, we synthesize emerging evidence from preclinical models and human studies demonstrating that GLP-1 receptor (GLP-1R) signaling modulates multiple cognitive domains, including reward and motivational processes relevant to obesity and substance use disorder, affective-related behaviors, and learning and memory. We propose a unifying framework in which GLP-1R signaling acts as a key interoceptive indicator of energy status, dynamically modulating cognitive and behavioral output in accordance with metabolic state. In animal models, GLP-1R activation dampens effort-based seeking for palatable food and addictive drugs alike, exerts bidirectional effects on affective behavior (e.g., anxiety-like behavior), and promotes synaptic plasticity, learning, and neuroprotection. Clinical studies further indicate that GLP-1R agonists alter neural responses to reward-related cues, influence mood-related outcomes, and are associated with reduced risk of cognitive decline, although results pertaining to benefits in neurodegenerative disease remain mixed. Collectively, these data position GLP-1R signaling as a metabolic-cognitive interface linking internal energy status to reward processing, affective regulation, and memory, and highlight the importance of disentangling direct central actions from indirect secondary metabolic effects when evaluating the therapeutic potential of GLP-1-based interventions for psychiatric and cognitive disorders.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.